Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | PARL | Q9H300 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64827 | 0.89 | PARL (0.31) | PARLCA2 | |
| SCHEMBL21409789 | 0.84 | — | — | |
| Phosphine SCHEMBL19611314 | 0.84 | — | — | |
| SCHEMBL4653374 | 0.84 | — | — | |
| SCHEMBL25175816 | 0.84 | — | — | |
| SCHEMBL23174460 | 0.84 | — | — | |
| Ammonia Solution, Strong SCHEMBL1914672 | 0.84 | — | — | |
| SCHEMBL21409686 | 0.84 | — | — | |
| SCHEMBL21409683 | 0.84 | — | — | |
| SCHEMBL6270996 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339850-A1 | CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2023-10-26 | — | — | US | claimed |
| EP-4100399-A1 | CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF | London Pharmaceuticals and Research Corporation (CA) | 2022-12-14 | — | — | EP | claimed |
| CN-115052868-A | Cannabinoid sulfate, and salts and uses thereof | 伦敦制药与研究公司 | 2022-09-13 | — | — | CN | claimed |
| WO-2021155474-A1 | CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2021-08-12 | — | — | WO | claimed |
| EP-3215567-B1 | METHOD OF PRODUCTION OF GRAFT CO-POLYMER EXCIPIENT WITH A SUPERIOR PEPTIDE AND PROTEIN BINDING PROPERTY | PHARMAIN CORP (US) | 2021-05-19 | — | — | EP | claimed |
| US-10882961-B2 | Method of production of graft co-polymer excipient with a superior peptide and protein binding property | PharmalN Corporation (US) | 2021-01-05 | — | — | US | claimed |
| CN-107531994-B | Method for preparing graft copolymer excipient with excellent peptide and protein binding property | 药明公司 | 2020-12-01 | — | — | CN | claimed |
| US-20180312642-A1 | METHOD OF PRODUCTION OF GRAFT CO-POLYMER EXCIPIENT WITH A SUPERIOR PEPTIDE AND PROTEIN BINDING PROPERTY | PHARMAIN CORPORATION (US) | 2018-11-01 | — | — | US | claimed |
| US-10035885-B2 | Method of production of graft co-polymer excipient with a superior peptide and protein binding property | PHARMAIN CORPORATION (US) | 2018-07-31 | — | — | US | claimed |
| CN-107531994-A | Method for preparing graft copolymer excipient with excellent peptide and protein binding property | 药明公司 | 2018-01-02 | — | — | CN | claimed |
| EP-3215567-A1 | METHOD OF PRODUCTION OF GRAFT CO-POLYMER EXCIPIENT WITH A SUPERIOR PEPTIDE AND PROTEIN BINDING PROPERTY | Pharmain Corporation (US) | 2017-09-13 | — | — | EP | claimed |
| US-20160362523-A1 | METHOD OF PRODUCTION OF GRAFT CO-POLYMER EXCIPIENT WITH A SUPERIOR PEPTIDE AND PROTEIN BINDING PROPERTY | PHARMAIN CORPORATION (US) | 2016-12-15 | — | — | US | claimed |
| WO-2016073518-A1 | METHOD OF PRODUCTION OF GRAFT CO-POLYMER EXCIPIENT WITH A SUPERIOR PEPTIDE AND PROTEIN BINDING PROPERTY | PHARMAIN CORPORATION (US) | 2016-05-12 | — | — | WO | claimed |
| CN-122084910-A | Magnetic bead-antibody complex for detecting beta-amyloid 42 as well as preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-120064647-A | Kit for detecting granzyme B, preparation method and application | 重庆大学附属肿瘤医院 | 2025-05-30 | — | — | CN | disclosed |
| US-20240189327-A1 | SYNERGISTIC CANNABINOID ESTERS, THEIR SALTS AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2024-06-13 | — | — | US | disclosed |
| EP-1971372-A2 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | Pharmain, Ltd. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007076371-A2 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070141145-A1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMALN LTD. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20020077697-A1 | Processed ratite carotid arteries as xenogeneic small bore vascular grafts | CENTERPULSE BIOLOGICS INC. | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141145-A1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | CD44, HDGF, MTDH | CA5A 2694/4885CA5B 2531/4885PARL 3382/4885 |
| US-20230339850-A1 | CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF | CNR2, CNR1, GPR18 | CA5A 3527/4885CA5B 3266/4885PARL 3311/4885 |
| US-20240189327-A1 | SYNERGISTIC CANNABINOID ESTERS, THEIR SALTS AND USES THEREOF | CNR2, CNR1, GPR18 | CA5A 3310/4885CA5B 2743/4885PARL 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.